All In Biotech

Drug Trial Radar · NCT05683886

A Study of KC1036 in Patients with Advanced Thymic Tumors

A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors

Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 22, 2023

Primary completion

Feb 2025

Study completion Feb 2026

Sponsor

Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm,open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.

Conditions

  • Thymic Tumors

Interventions

  • KC1036Drug

    Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: approximately 2 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.